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ADENOVIRUS INFECTION (AI) AND DISEASE (AD) IN PEDIATRIC 
MATCHED UNRELATED DONOR BONE MARROW TRANSPLANT (BMT) 
PATIENTS RECEIVING EITHER ANTI-THYMOCYTE GLOBULIN (ATG) 
OR CAMPATH DURING CONDITIONING 
Myers, G.D.Z; Heslop, Hi; Kuehtde, I. t; Bollard, C.I; Detain/e*', G J; 
Ka~mlce, R. 1 1. Baylor College of 3/ledMne, Hoztsto~z, TX; 2. Texas Chil- 
cl're~  Hospital, HoHstoll, 77(. 
Recent reports have shown an increased incidence of AI in 
patients treated with Campath. The incidence of AI/AD was 
compared in 112 patients at our institution who underwent allo- 
geneic BMT receiving either ATG or Campath during condition- 
ing. AI was defined as isolation of adenovirus in culture or detec- 
tion by PCR from a single site. AD was defined as 
isolation/detection in blood or end organ involvement. Two 
patients with AI were excluded for receiving both medications. AI
was present in 25% overall (27/I10), AD was seen in 1.8% 
(2/i10). Of those receiving ATG (72/110), AI rate was 24% 
(17/72) and AD was in 1.4% (l/72); for those receiving Campath 
(43/112) AI rate was 28% (13/43) and AD was in 2.3% (1/43) 
(p=0.69). Mortality for the entire group was 30% (34/112). Two 
of the 27 patients with AI died of AD. One patient received Cam- 
path and had grade 1V graft versus host disease (GVH). The sec- 
ond patient received ATG and had no GVH. These findings ug- 
gest no difference in adenovirus associated infection and disease 
rates among those receiving conditioning containing either ATG 
or Campath. Several risk factors have been identified for AD in 
the BMT patient including prolonged CD4 suppression, grade II- 
IV GVH and viral isolation from multiple sites. We plan to fur- 
ther delineate risk factors by measuring viral load by real time 
PCR and monitoring adenovirus pecific immune response by 
Elispot. 
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DETECTION OF PEPTIDE-SPECIFIC ALLOREACTIVE T CELLS USING 
HLA CLASS I TETRAMERS 
~fTaitelegg, A.M.; 3/lmh'igal, 7;  Bm'ber, L.D. A77tho W Nohm Resea'l~ch 
bzstitHte, LozMo~z, Lo~do1~, Ulzited Kilzgdom. 
After stem cell or solid organ transplantation alloreactive T cells 
are stimulated and form a vigorous response to allogeneic HLA 
molecules. In the absence of aggressive imrnunosuppression 
strategies these cells cause graft versus host disease and graft rejec- 
tion. We sought o obtain evidence that the magnitude of the T 
ceil alloresponse results from the numerous potential antigenic 
targets created by the diverse range of peptides presented by allo- 
geneic HLA molecules. HLA tetrameric complexes were used to 
identify the ligands recognised by alloreactive T cells. A panel of 
A*0201/peptide t trameric complexes was generated representing 
abundant self peptides known to bind endogenously to 3.*'020I. 
Alloreactive CDS+ T cell lines specific for A*0201 were stimulated 
in vitro and screened for tetramer binding by flow cytomerry to 
identify and quantify cells that recognise ach HLA/peptide 
alloantigen. For all HLA/peptide combinations tested a small 
population of tetranaer binding CD8+ T ceils was found. 
Tetramer-binding T cells exhibited exquisite specificity for the 
peptide bound by allogeneic A*0201 and peptide specific alloreac- 
tire T cells could be induced by both disparate and veW limited 
HLA mismatches. These alloreactive T cells were shown to origi- 
nate from the memory T cell population indicating that they rep- 
resent cross reactive T cells previously stimulated by antigenic 
peptides from foreign pathogens presented by self MHC mole- 
cules. TNF c~ expression along with enhanced expression of per- 
forin and IFN 7 was detected in tetramer binding cells demon- 
strating that the peptide alloreactive T cells are functional. Our 
results provide evidence to support he theory that the vigorous 
alloreactive T cell response is caused by the summation f numer- 
ous responses to each of the peptides bound by the allogeneic 
HLA molecules and show that tetramers can be used to detect 
functional alloreactive T cells. The panel of tetramers i currently 
being used to screen for alloreactive T cells in HLA mismatched 
transplant patients. 
Poster  P resentat ions  - Sess ion  I 
62 
SELECTIVELY DEPLETING HOST-REACTIVE T CELLS FROM PERIPH- 
ERAL BLOOD STEM CELL ALLOGRAFTS - PRELIMINARY RESULTS OF 
A FEASIBILITY STUDY 
Solommz, S.1; Tl"aJz, T.1; Carter, C.S.I; Battiwalla, iVl.1; Childs, R.~; 
Dzmbav, C.EJ; You*@ N.SJ; Het~sel, N.I; ~Visch, L.l; Schi~dle*', if.e; 
Vitetta, E.S.e; Read, E.ff J; Ba,v-ett, ft.1 1. Stem Cell Allot*'amTdal~ta- 
tio*~ SectioJz, NHLBI, NatioJ~al bTstitzttes of Healt,}, l?ethesda, 3ID; 
2. U~iversity of Texas SoHthvaestelw, Dallas, TX. 
Ex vivo selective depletion (SD) is a strategy to prevent graft- 
versus-host-disease (GVHD), in which host-reactive donor lym- 
phocytes are selectively eliminated from a peripheral blood stem 
cell (PBSC) allograft while conserving useful donor immune func- 
tion. We initiated a clinical study to assess the feasibility of this 
approach in the setting of nonmyeloablative st m cell transplants 
(NST) in older patients with hematologic malignancies. Three 
patients (median age 66 years) with advanced myelodysplastic syn- 
drome (2 RAEB, 1 RAEB-AML) received alow intensity prepara- 
tive regimen consisting of cyclophosphamide and fludarabine, fol- 
lowed by a "selectively-depleted" PBSC allograft from an 
HLA-identical sibling donor. To obtain such a graft, a 
positive/negative s lection (Isolex 300i) was performed on G- 
CSF-mobilized onor peripheral blood to generate a stein celI- 
rich product containing a CD34+ cell dose of >3xl06/kg and a 
CD3+ cell dose of 5xl04/kg. The remaining fraction was then co- 
cultured with irradiated lymphocytes obtained from the patient 
before transplant by apheresis. After 72 hours an anti-CD25 
imnmnoto.'dn, RFI'5-SMPT-dgA, was added to remove alloreact- 
ing cells. The washed T cell product (CD3+ cell dose of 1-2 x 
10e/kg) was infused following the preparative regimen, together 
with the stem cell-rich product. All patients received post-trans- 
plant immunosuppression with cyclosporine for a minimum of 30 
days, followed by dose reduction depending on the degree of 
donor lymphocyte chimerism. SD lymphocytes were successfully 
generated for all patients, meeting release criteria for cell num- 
bers, viability, and sterility and were infused safely without any 
untoward effects. All patients achieved 100% donor T cell 
engraftment by day 30, comparable to that seen with unmanipu- 
fated NST. Rapidly-resolving rades I and II skin-GVHD 
occurred in two patients, and no patient died of transplant-related 
causes. This is in contrast o a 35% TRM seen in a previous 
cohort of older patients receiving the same protocol without SD. 
Two survive 43-365 days post transplant, one patient (with AML 
at time of transplant) died day 200 of progressive l ukemia. These 
preliminary results are promising and demonstrate he ability of 
SD lymphocytes to engraft. 
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ANTI-LEUKEMIC ACTIVITY OF CHRONIC GRAFT-VERSUS-HOST DIS- 
EASE FOLLOWING ALLOGENEIC BONE MARROW TRANSPLANTATION 
IN ADULT PATIENTS WITH PHILADELPHIA CHROMOSOME-POSITIVE 
ACUTE LYMPHOBLASTIC LEUKEMIA 
Lee, S.; K#n, D.; Kim, Y.; Kim, K; Hwalzg, J.; Kim, H.; Mira I4~; 
Kim, C. Catholic Hematopoietic Stem Cell Tra~zsplaJztatiml Ce~zter, The 
Catholic U~dversity of Kol"ea, Seozd, South Korea. 
The aim of this study was to evaluate the outcomes for Philadel- 
phia chromosome-positive acute lymphoblastic leukemia (Ph+ 
ALL) in remission treated with allogeneic bone marrow rransplan 
tation (BMT). Twenty-three adults were entered onto this study. 
The 2-year probabilities of relapse and disease-fi'ee survival (DFS) 
were 39.4% and 43.5%, respectively. The presence of chronic 
graft-versus-host disease (GVHD) was found to be an independ- 
ent predictive factor affecting lower relapse and DFS. To monitor 
the BCR-ABL transcript, we also analyzed 48 bone marrow sam- 
pies of 8 patients using real-time quantitative r verse transcrip- 
tion-polymerase chain reaction (RT-PCR). The kinetics of the 
normalized amount of BCR-ABL transcript (BCR-ABL/ABL) 
were well correlated with their clinical courses. In 6 patients with 
continuous remission after BMT, a rapid decrease in BCR-ABL 
amount o the PCR negative status after the development of 
chronic GVHD was observed. Meanwhile, routine bone marrow 
BB&MT s3 
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examination of 2 patients revealed PCR positivity with a 3 or 4- 
log increases of normalized BCR-ABL amount and subsequent 
hematologic relapse, which occurred 2 and 4 months later, respec- 
tively. Although our data should be interpreted cautiously, the 
presence of chronic GVHD may reduce the risk of relapse in Ph+ 
ALL. Real-time quantitative RT-PCR appears to be a useful test 
for BCR-ABL transcript monitoring. 
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ALLOGRAFTING WITH FLUDARABINE AND ATG AFTER FAILED 
ENGRAFTMENT OF AUTOLOGOUS PERIPHERAL BLOOD STEM CELLS 
Bayer, R.; Focazio, B.; Johl~, V.; Loscalz~o, ft.; Buchbi~der, A. North 
Shore UlTiversity Hospital, Ma~hasset, NK 
High-dose myeloablative r gimens with autologous stem cell 
transplantation have been pursued as a consolidation strategy in 
first remission AML patients. We report two patients with AML 
who received autologous tem cell transplants in first CR. Both 
patients received similar regimens and failed to engraft heir 
autologous blood stem cells. Both were then given Fludarabine 
and ATG with subsequent engraftment of cells from an HLA 
matched sibling. Patient A.S. is a 32 y.o male diagnosed with 
AML, FAB subtype M2, with normal cytogenetics who received 
induction chemotherapy with Ara-C 100mg/m2 x7 days, 
Daunorubicin 40mg/m2 x3 and VP16 40mg/m2 x3. His intensifi- 
cation/mobil ization i cluded Ara-C 2gin/m2 x8 and VPI6 
10mg/kg x4. The regimen used for autologous stem cell transplant 
was Busulfan p.o. lmg/kg x16 doses and VP16 60mg/kg xl. He 
received 15.6 x 10 E6 CD34 cells/kg bodyweight. On day 52 there 
was no sign of engraftment. He was then given Fludarabine 
30mg/m2 x4 doses and ATG 15mg/kg x6 doses. Peripheral blood 
stem cells, 4.2 x 10 E6 CD34 cells/kg, were given from his HLA 
matched brother. Engraftment was noted on Day 12 post trans- 
plant. He had no signs of GVHD. He is now 100% donor, con- 
firmed by variable number tandem repeats (VNTR). Patient R.S. 
is a 46 y.o male who was diagnosed with AML, FAB subtype M2, 
with normal cytogenetics. His induction chemotherapy consisted 
ofAra-C 100mg/m2 x7 days and Daunorubicin 30rag/m2 x3 days. 
This was followed by an intensification/mobilization regimen of 
Ara-C 2gm/m2 x8 doses and VP16 10mg/kg x4 doses. He received 
Busulfan 1V 0.8mg/kg x16 doses and VP16 60mg/kg xl dose as a 
regimen for his autologous stem cell transplant. He received 11 x 
10 E6 CD34 cells/kg bodyweight. On day 36 there was no 
engraftment. He was then given Fludarabine 30rag/m2 x4 doses 
and ATG 15mg/kg x6 doses. He was given peripheral blood stem 
cells, 2.1 x 10 E6 CD34 cells, from his HLA matched brother. 
Engraftment was noted on Day 7 post transplant. The patient 
developed Grade I GVHD which responded to treatment with 
Prednisone. He is presently 98% donor confirmed by VNTR. We 
conclude that Fludarabine and Antithymocyte globulin is a safe 
and effective regimen for allografting after failed engraftment of
autologous peripheral blood stem cells in patients with AML. 
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THE CD4 PEPTIDE ANALOGUE 802-2 INHIBITS PROLIFERATION 
OF BOTH THI AND TH2 CELLS IN RESPONSE TO ALLOGENEIC 
STIMULATION 
Zbu, Z.; Mooketjee, B.; Ko~zgold, R.; Flome~berg, N. Tbomas Jeffer- 
so~ University School of Medich~e, Philadelphia, PA. 
Engagement of CD4 and the T cell ?eceptor (TCR)-CD3 com- 
plex generates signals which lead, in part, to the activation of 
helper T (Th) cells. Activated Th cells contribute to graft-versus- 
host disease (GVHD) arising from allogeneic MHC class II and 
minor histocompatibility antigenic differences. The 802-2 syn- 
thetic cyclic heptapeptide, designed and confirmed by NMR spec- 
troscopy to mimic the D1-CC' loop of CD4, inhibits Th cell acti- 
vation in human and murine systems. Since Th l  cells appear to be 
more important in the pathogenesis of acute GVHD than their 
Th2 counterparts, the efficacy of 802-2 in modulating allogeneic 
responses of both Th l  and Th2 cells was therefore tested. Prima- 
i T polarization of Th cells was performed by stimulating purified 
CD4+ cells from healthy donors with irradiated EBV transformed 
B cells (EBV-B) obtained from unrelated, HLA ntismatched 
donors in the presence ofTh l  (IL-2 + IL-12) or Th2 (IL-2 + IL- 
4) polarizing cytokines. After similar restimulation on days 3 and 
6, cells were subsequently propagated in the presence irradiated 
autologous mononuclear cells through weekly allogeneic restimn- 
lation and biweekly cytokine supplementation. Th l  and Th2 cells 
from 3-4 week old cultures were harvested and stimulated with 
irradiated EBV-B in the presence of IL-2 with and without 802-2 
peptide. The presence of 802-2 (200gM) reduced the proliferation 
of both Thl  and Th2 cells to near background levels. Delaying 
exposure to 802-2 by more than 72 hours after allogeneic stimula- 
tion substantially reduced or eliminated its ability to inhibit prolif- 
eration. While murine Th cells, activated in vivo, in the presence 
of 802-2 appear to undergo apoptosis, it has not been possible to 
similarly demonstrate apoptosis of human Th cells activated in 
vitro in the presence of 802-2. The lack of inhibitory effects of 
802-2 when added at later time points after allostimulation rules 
out a non-specific inhibition of cellular proliferation or toxicity. 
We hypothesize that 802-2 inhibits multimerization of the 
CD4/MHC class-II/antigen/TCR complex during allostinmla- 
tion. The resultant spatial disruption of the associated signaling 
molecules leads to abrogation of the signals for cell proliferation 
and may render the Th cells anergic, as occurs in other situations 
where lymphocytes receive partial or disordered activation signals. 
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ADDING MYCOPHENOLATE MOFETIL (MMF) AND ATGAM TO 
CYCLOSPORIN DECREASES SEVERE GVHD AND TRANSPLANT-RELAT- 
ED MORTALITY (TRM) AFTER NON-MYELOABLATIVE ALLOGENEIC 
PBSC TRANSPLANTATION (MINI-PBSCT) 
SchwareT; A.P.; Spe~ce~, A.; Kapusc#~ski, M.; ~/btirhead, ,7.Boise Mar- 
row Tra~lsplantatio~, Alfi'ed Hospital, Melbou~n~e, 7C, Amtralia. 
INTRODUCTION:  Mini-PBSCT can provide cure for some 
older or less fit patients with hematological malignancies not eligi- 
ble for standard PBSCT. Mini-PBSCT uses lower doses of condi- 
tioning chemotherapy and/or radiotherapy to improve the safety 
of allogeneic PBSCT and relies on the graft-versus-tumor (GVT) 
effect for cure. METHODS: We treated 31 patients, not eligible 
for standard PBSCT, with mini-PBSCT: median age 51 (29-63) 
yrs; 20 male, 11 female; 25 advanced isease (6 AML)CR1, 5 
NHL, 4 myeloma, 2 MDS, 2 HD, 2 mycosis fungoides, and 1 
each of CML-BC, YValdenstom's macroglobulinemia, myelofibro- 
sis, T-PLL) and 6 early disease (2 AML-CR1, 2 CLL, l CML, 1 
LG-NHL). All patients received fludarabine (25 mg/m 2 x5) and 
melphalan 140 mg/rn 2prior to undergoing HLA-matched (22 sib- 
ling, 1 cousin, 8 unrelated) donor mini-PBSCT. The first 12 
patients received CSA 3 mg/m2/day M alone as GVHD prophy- 
laxis in an attempt o not excessively inhibit a potential GVT 
effect. An unacceptably high incidence of severe acute GVHD and 
TRM occurred with a low relapse rate. Therefore, we modified 
the protocol to include ATGAM 15 mg/kg from day 4 to +5 and 
MMF 15 mg/m 2 from day 0 to +27 for all subsequent patients 
(n=19). RESULTS:  Although more patients in 
CSA/ATGANUMMF cohort than CSA alone cohort underwent 
mini-PBSCT with unrelated onors (42% vs 0%) the incidence of
severe acute and extensive chronic GVHD was less, 100 day TRM 
was less (see Table) and overall TRM was less (26% vs 42%; 
p=0.38) in CSA/ATGAM/MMF cohort. To date, the relapse rate 
was similar in both cohorts although the follow-up of survivors 
was shorter in CSA/ATGAMJMMF cohort - 504 (19-634) days vs 
942 (865-1089) days. CHIMERISM:  T cell and myeloid 
chimerism using VNTR polymorphism analysis was assessed in 
CSA/ATGAM/MMF cohort but not the earlier CSA alone 
cohort. Of 14 evaluable patients 13 showed sustained >90-95% 
donor chinaerism by 1 month post mini-PBSCT. The remaining 
patient achieved <50% donor chimerism which was managed by 
ceasing MMF; >90% donor chimerism rapidly developed accom- 
panied by the onset of severe acute GVHD. No graft rejection 
was noted in either cohort. CONCLUSION: The combination 
of CSA/ATGAM/MMF appears to be effective GVHD prophy- 
laxis for older, less fit patients with advanced isease undergoing 
mini-PBSCT. 
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